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Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense
Oligonucleotide Against Tumors of Diverse
Histologic Origins
Oliver Gautschi, Stefan Tschopp, Robert A. Olie, Siaˆn H. Leech, A. Paula
Simo˜es-Wu¨st, Annemarie Ziegler, Bettina Baumann, Bernhard Odermatt,
Jonathan Hall, Rolf A. Stahel, Uwe Zangemeister-Wittke
Background: Increased expression of the anti-apoptotic pro-
teins Bcl-2 and Bcl-xL is involved in the development and
progression of many tumors. We recently reported that the
bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 in-
duces apoptosis in lung carcinoma cells. To further assess the
therapeutic potential of oligonucleotide 4625, we investigated
its effect on a series of human tumor cell lines of diverse
histologic origins in vitro and in vivo. Methods: Oligonucleo-
tide 4625-mediated inhibition of bcl-2 and bcl-xL expression
in vitro was measured in breast carcinoma cells with the use
of reverse transcription–polymerase chain reaction (PCR),
real-time PCR, and western blotting. Cytotoxicity was as-
sessed in several different cell lines by measurement of tu-
mor cell growth, propidium iodide uptake, and nuclear ap-
optosis. The in vivo activity of oligonucleotide 4625 was
determined by the inhibition of growth of established tumor
xenografts in nude mice, immunohistochemical staining of
Bcl-2 and Bcl-x proteins in the tumors, and western blotting
of tumor lysates. Apoptosis in tumor xenografts was detected
with the use of in situ TUNEL (i.e., terminal deoxynucleo-
tidyl transferase-mediated deoxyuridine triphosphate-
digoxigenin nick end labeling) staining. All statistical tests
are two-sided. Results: In breast carcinoma cells, oligo-
nucleotide 4625 treatment reduced bcl-2 and bcl-xL messen-
ger RNA levels in a dose-dependent manner. At 600 nM,
oligonucleotide 4625 reduced Bcl-2 and Bcl-xL protein levels
to 25% (95% confidence interval [CI] = 16% to 34%) and
20% (95% CI = 14% to 26%), respectively, of the levels in
untreated cells and it decreased viability in all cell lines
mainly by inducing apoptosis. In vivo, oligonucleotide 4625
statistically significantly inhibited the growth of breast and
colorectal carcinoma xenografts by 51% (95% CI = 28% to
74%) and 59% (95% CI = 44% to 74%), respectively, rela-
tive to those treated with control oligonucleotide 4626; it also
reduced Bcl-2 and Bcl-xL protein levels and induced tumor
cell apoptosis. Conclusion: The bcl-2/bcl-xL-bispecific anti-
sense oligonucleotide 4625 merits further study as a novel
compound for cancer therapy. [J Natl Cancer Inst 2001;93:
463–71]
Impaired apoptosis due to blockade of the cell death-
signaling pathways is involved in tumor initiation and progres-
sion, since apoptosis normally eliminates cells with damaged
DNA or aberrant cell cycling, i.e., cells with increased malignant
potential. From this recognition, a concept emerged that eleva-
tion of the threshold at which apoptosis is initiated represents a
central step for tumor development and drug resistance. The
structurally related Bcl-2 family proteins either inhibit or pro-
mote apoptosis, thereby regulating cell death in a rheostatic man-
ner (1). The anti-apoptotic family members Bcl-2 and Bcl-xL
both localize to cellular membranes, particularly in mitochon-
dria, where they stabilize the transmembrane potential and
reduce membrane permeability. This action inhibits the release
from mitochondria of substances involved in either signaling
or execution of apoptosis, such as cytochrome c, procaspase 3,
and apoptosis-inducing factor (2). Although the issue is cur-
rently disputed, Bcl-xL may also inhibit apoptosis by binding
to Apaf-1, thereby preventing its association with procaspase 9
and cytochrome c and the subsequent activation of downstream
effector caspases (3). Although Bcl-2 and Bcl-xL seem to be
functionally indistinguishable, there is evidence that they differ
in their ability to protect cells from different apoptotic stimuli
(4,5). In addition, Bcl-2 seems to contribute to tumor cell sur-
vival by diminishing the rate of cell proliferation (6) and by
allowing tumor cells to escape from destruction by effector cells
of the immune system (7).
The majority of solid tumors are protected by at least one of
the two cell death antagonists, Bcl-2 or Bcl-xL. Although the
relative expression levels of Bcl-2 and Bcl-xL vary, depending
on the type and stage of the tumor, evidence for Bcl-2 and
Bcl-xL overexpression as negative prognostic markers is pro-
vided by several findings: 1) Bcl-2 expression in non-small-cell
lung carcinoma and estrogen receptor-positive breast carcinoma
is associated with lymph node invasion (8,9); 2) Bcl-xL expres-
sion in breast and colorectal carcinomas is associated with
advanced-stage disease (10,11); 3) Bcl-2 and Bcl-xL expression
in prostate carcinoma is associated with tumor grade, metastatic
potential, recurrence after prostatectomy, and radioresistance
(12,13); and 4) overexpression of Bcl-2 in cutaneous malignant
melanoma is associated with shorter survival (14). In tumors
where Bcl-2 and Bcl-xL are coexpressed, it is difficult to predict
which of the two proteins is more critical for survival and, thus,
the more relevant target for gene therapy approaches. Moreover,
tumor cells are able to switch expression from Bcl-2 to Bcl-xL
(15), and forced overexpression of Bcl-2 has been reported to
result in the reciprocal inhibition of Bcl-xL expression (16). In
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view of this complexity, the simultaneous inhibition of Bcl-2
and Bcl-xL expression in tumors by a single compound repre-
sents an appealing concept.
Antisense therapy holds the promise for selective silencing of
genes, e.g., those involved in the resistance of cells to apoptosis
induction, such as bcl-2 or bcl-x. Antisense oligonucleotides act
by specifically hybridizing with complementary messenger
RNA (mRNA) sequences based on Watson–Crick base pairing,
thereby inhibiting gene expression primarily by activation of
ribonuclease (RNase) H, which subsequently cleaves the target
mRNA (17). Second-generation antisense oligonucleotides with
a phosphorothioate backbone and up to five nucleotides at both
the 5 and the 3 end modified by methoxy-ethoxy (MOE) resi-
dues at the 2--position of the deoxyribose show enhanced
RNA-binding affinity compared with their first-generation 2-
deoxy counterparts. Moreover, owing to the central 2-deoxy
gap, these antisense compounds are still capable of activating
RNase H (18). Antisense oligonucleotides complementary to
either the bcl-2 or the bcl-xL mRNA have previously demon-
strated activity against tumor cells of various origins (19–24).
Bcl-2 antisense oligonucleotides in combination with chemo-
therapy are currently in phase I/II clinical trials for the treatment
of patients with lymphoma and malignant melanoma, and further
trials with patients with lung, prostate, renal, or breast carcinoma
are ongoing or planned.
Based on the assumption that simultaneous inhibition of bcl-2
and bcl-xL expression with a single compound might be thera-
peutically more promising than the inhibition of either alone, we
have recently designed the bcl-2/bcl-xL-bispecific antisense oli-
gonucleotide 4625 and reported its ability to inhibit the expres-
sion of bcl-2 and bcl-xL and to induce apoptosis in lung carci-
noma cells in vitro (25). In the present study, we investigated the
ability of antisense oligonucleotide 4625 to inhibit the expres-
sion of bcl-2 and bcl-xL in a representative breast carcinoma cell
line and to inhibit the growth and induce death in cell lines from
lung, breast, colorectal, and prostate carcinomas and from ma-
lignant melanoma in vitro. In addition, the ability of oligo-
nucleotide 4625 to inhibit tumor growth and to reduce the Bcl-2
and Bcl-xL proteins in vivo was examined in established tumor
xenografts in nude mice. Our data demonstrate the potent anti-
tumor activity of oligonucleotide 4625 against a series of tumor
cell lines in vitro and in vivo and suggest its use in cancer
therapy.
MATERIALS AND METHODS
Cell Lines
The following nine human tumor cell lines of different histologic origins were
obtained from commercial cell culture collections unless indicated otherwise:
SW2 (small-cell lung carcinoma), NCI-H125 (non-small-cell lung carcinoma),
MDA-MB-231 (estrogen-independent breast adenocarcinoma), MCF-7 (estrogen-
dependent breast adenocarcinoma), Colo-320 (colorectal adenocarcinoma),
LoVo (colorectal adenocarcinoma), PC-3 (prostate adenocarcinoma), C4–2
(prostate adenocarcinoma; provided by Dr. G. Thalmann, University Hospital,
Bern, Switzerland), and A-375 (cutaneous malignant melanoma; provided by
Dr. R. Dummer, University Hospital, Zurich, Switzerland). MDA-MB-231 cells
were cultured in high-glucose Dulbeccos modified Eagle medium supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 50 IU/mL penicillin, and 50 g/mL
streptomycin. All other cell lines were maintained in RPMI-1640 medium
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 2.5 g/L glucose, 10
mM HEPES, 1 mM sodium pyruvate, 50 IU/mL penicillin, and 50 g/mL strep-
tomycin. Cultures were maintained at 37 °C in a humidified atmosphere con-
taining 5% CO2. All cell culture reagents were obtained from Hyclone Europe,
Ltd. (Cramlington, U.K.).
Oligonucleotides
Antisense oligonucleotide 4625 binds to a region of high homology shared
by bcl-2 and bcl-xL comprising nucleotides 605–624 and 687–706 of the two
mRNAs, respectively (25). These target sites are located 573 and 550 nucleotides
downstream of the AUG start site of the bcl-2 and bcl-xL mRNA, respectively.
Oligonucleotides 4626 and 4258 were used as scrambled sequence controls. All
oligonucleotides were 20-mers with a phosphorothioate backbone and nucleo-
tides at the 5 and 3 ends modified by MOE residues at the 2--position of the
deoxyribose (represented by underlined letters in the sequences shown below).
Oligonucleotides were synthesized as described previously (26) on an Oligopilot
II (Amersham Pharmacia Biotech, Uppsala, Sweden) at a 150- to 180-mol scale
on a polystyrene primer (Amersham Pharmacia Biotech) derivatized via a suc-
cinyl arm by the first corresponding 2-MOE 3 nucleoside. Crude oligonucle-
otides were purified by reverse-phase high-performance liquid chromatography.
Purity was assessed by capillary gel electrophoresis, the phosphodiester content
was checked with 31P-nuclear magnetic resonance, and the oligonucleotides
were characterized by MALDI-TOF MS (i.e., matrix-assisted laser desorption
ionization time of flight mass spectrometry). Oligonucleotides displayed a length
purity higher than 95% with a phosphodiester content of less than 0.3%.
The sequences were as follows: 4625, 5-AAGGCATCCCAGCCTCCGTT-3
(antisense); 4626, 5-CACGTCACGCGCGCACTATT-3 (control); and 4258,
5-CATATCACGCGCGCACTATG-3 (control).
Treatment of Cells With Oligonucleotides
In vitro, oligonucleotides were delivered to the cells in the form of complexes
with the transfection reagent Lipofectin (Life Technologies, Inc. [GIBCO BRL],
Glasgow, U.K.) as described previously (25). Lipofectin (50 g/mL) was al-
lowed to complex with oligonucleotides, and this solution was further diluted to
the desired concentration in serum and antibiotic-free medium before addition
to the cells. Except for the growth assays described below, cells were incubated
with oligonucleotides and Lipofectin for 20 hours, after which the Lipofectin
solution was replaced by standard cell culture medium as described above.
Reverse Transcription–Polymerase Chain Reaction
One microgram of total RNA was reversed transcribed for 1 hour at 37 °C in
20-L reactions containing 50 mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl2, 500
M each deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate
(dGTP), deoxycytidine triphosphate (dCTP), and deoxythymidine triphosphate
(dTTP), 7.5 g/mL random hexamers (Promega Corp., Madison, WI), 10 mM
dithiothreitol, and 200 U Moloney murine leukemia virus reverse transcriptase
(Life Technologies, Inc.). For the detection of bcl-2 mRNA, 2 L of the reverse-
transcribed material was amplified by polymerase chain reaction (PCR) in 50-L
reactions containing 10 mM Tris (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 200 M
each dATP, dGTP, dCTP, and dTTP, 0.2 M of each primer, and 0.25 U
Amplitaq DNA polymerase (Applied Biosystems [formerly Perkin-Elmer
Applied Biosystems], Foster City, CA), for a total of 30 cycles consisting of
94 °C for 45 seconds, 55 °C for 60 seconds, and 72 °C for 60 seconds, with a
final extension step for 10 minutes at 72 °C. Detection of bcl-xL mRNA was
done under similar conditions, except that 1.5 mM MgCl2 was used in the PCR
reaction, and cycles were reduced to 28. To control for the presence and quantity
of RNA in each reaction, we reamplified 5 L of each PCR for 33 cycles under
similar conditions with primers for 2-microglobulin able to discriminate be-
tween complementary DNA (cDNA) and genomic DNA. Amplification products
were analyzed by electrophoresis in ethidium bromide-stained agarose gels.
Primer sequences were as follows: bcl-2, 5-GTGAACTGGGGGAGGATTGT-
3 (forward) and 5-GGAGAAATCAAACAGAGGCC-3 (reverse); bcl-xL, 5-
CCCAGAAAGGATACAGCTGG-3 (forward) and 5-GCGATCCGACTCAC-
CAATAC-3 (reverse); and 2-microglobulin, 5-GTGGAGCAT TCAGACTT-
GTCTTTCAGC-3 (forward) and 5-TTCACTCAATCCAAATGCGGCATCTTC-3
(reverse).
Real-Time PCR
Total RNA was isolated from cells by use of the RNeasy Mini Kit (Qiagen
AG, Basel, Switzerland). For cDNA synthesis, Taqman reverse transcription
reagents were used as described in the user’s manual of the ABI Prism 7700
Sequence Detection system, which was used for real-time PCR amplification
following the Taqman Universal PCR Master Mix protocol (Perkin-Elmer Ap-
plied Biosystems). Relative quantification of gene expression was performed as
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described in the manual with the use of ribosomal RNA (rRNA) as an internal
standard and the comparative threshold cycle method. Briefly, 0.5 g of total
RNA was used to generate cDNA by the reverse transcription reaction. The bcl-2
and bcl-xL cDNAs were amplified with the use of primers and Taqman probes
that had been selected with the use of the Primer Express Applications-Based
Primer Design Software (Perkin-Elmer Applied Biosystems). For bcl-2, primers
with the sequences 5-CATGTGTGTGGAGAGCGTCAA-3 and 5-
GCCGGTTCAGGTACTCAGT CA-3were used, together with a Taqman probe of
sequence 5-CCTGGTGGACAACATCGCCCTGT-3. For bcl-xL, primers with
the sequences 5-TCCTTGTCTACGCTTTCCACG-3 and 5-GGTCGCAT
TGTGGCCTTT-3 were used together with a Taqman probe of sequence 5-
ACAGTGCCCCGCCGAAGGAGA-3. The bcl-2 and bcl-xL probes were labeled
at the 5 end with the reporter dye 6-carboxy-fluorescein and at the 3 end with
the quencher 6-carboxy-tetramethyl-rhodamine. A Basic Local Alignment
Search Tool (BLAST) search of the National Center for Biotechnology Infor-
mation (NCBI) database containing all sequences in the GenBank, European
Molecular Biology Laboratory (EMBL) database, and the DNA Database of
Japan (DDBJ) revealed no homology of the primer and probe sequences to any
other known human genes. Data are presented relative to an untreated control
sample chosen as calibrator. The range of a given sample relative to the cali-
brator was always less than 10 %.
Western Blot Analysis
Lysates from cells treated with oligonucleotides were subjected to western
blot analysis as described previously (23). Twenty micrograms of soluble protein
per sample was separated by 12% polyacrylamide gel containing sodium dodecyl
sulfate and transferred to a polyvinylidene fluoride membrane in a semidry
blotting chamber for 1 hour. The blots were blocked in Tris-buffered saline
containing 5% bovine serum albumin (BSA) and 5% nonfat dry milk and then
incubated overnight at 4 °C with mouse anti-human Bcl-2 monoclonal antibody
(Dako Diagnostics AG, Glostrup, Denmark) or rabbit anti-human Bcl-x poly-
clonal antibody (Transduction Laboratories, Lexington, KY). Actin, stained with
a mouse anti-actin monoclonal antibody (ICN Biomedicals, Inc., Aurora, OH),
was used as a loading control. For the detection of the primary antibodies, we
incubated blots with rabbit anti-mouse or goat anti-rabbit immunoglobulin (Ig)
peroxidase conjugates (Sigma Chemical Co., St. Louis, MO), respectively, for 1
hour at room temperature. Antibodies were added in Tris-buffered saline con-
taining 1% BSA, 1% nonfat dry milk, and 0.05% Tween 20 (Sigma Chemical
Co.). Visualization of the immunocomplexes was performed by enhanced
chemiluminescence with the use of the ECL™ Kit (Amersham Pharmacia
Biotech), followed by exposure to x-ray films. Relative protein levels were
quantified with the use of Scion software (Scion Corp., Frederick, MD) on
scanned films.
Measurement of Cell Growth Inhibition
Effects of oligonucleotides on cell growth were determined as described pre-
viously (23) with the use of a colorimetric assay based on the reduction of
the tetrazolium salt MTT [i.e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] by mitochondrial dehydrogenases in viable cells. For each experiment,
cells were seeded in 96-well plates and cultured for 24 hours. Oligonucleotides were
then added in the form of complexes with Lipofectin up to a total volume of 100 L,
and cells were incubated at 37 °C. Seventy-two hours after the treatment was started,
10 L of MTT reagent (10 mg/mL) was added and allowed to react for 90 minutes
at 37 °C before the addition of 100 L of solubilization reagent (20% sodium
dodecyl sulfate in 50% dimethyl formamide [pH 4.7] and pH-adjusting solution [i.e.,
80% acetate and 20% 1 M HCl]). Substrate cleavage was monitored 12 hours later
at 570 nm by use of a SPECTRAmax 340 microplate reader and analyzed by use of
SOFTmax PRO software (Molecular Devices, Sunnyvale, CA).
Measurement of Cell Death and Apoptosis
Tumor cell death and apoptosis were measured 72 hours after the start of
treatment with 600 nM oligonucleotide by flow cytometry with the use of a
FACScalibur flow cytometer and the CellQuest software (Becton Dickinson,
Mountain View, CA). Cells were incubated with 10 g/mL propidium iodide for
5 minutes, and the fraction of cells with increased fluorescence intensity was
measured. Cell debris was excluded from the analysis by appropriate light scatter
gating. The apoptotic fraction was determined after the cells were made perme-
able with 50% ethanol for 30 minutes followed by incubation with 5 g/mL
RNase A for 30 minutes and incubation with 40 g/mL propidium iodide for 10
minutes. After clusters and fragments were excluded (27), cells with sub-G0/G1
DNA profiles were identified. In addition, apoptosis was assessed by nuclear
staining with Hoechst 33342 dye (Sigma Chemical Co.). For this purpose, cells
were pelleted, resuspended, and fixed in 4% paraformaldehyde–0.05% saponin–5
g/mL Hoechst 33342 for 15 minutes before cytospin centrifugation (20g for 3
minutes at room temperature). Cells were mounted with Mowiol (Calbiochem,
La Jolla, CA), and nuclei were observed by use of a Leica confocal laserscan
microscope equipped with SCANware software (Leitz, Wetzlar, Germany).
Images were processed with the use of the Imaris software (Bitplane, Zurich,
Switzerland).
Determination of Antitumor Activity In Vivo
Six- to 8-week-old female CD1 nu/nu (nude) mice were obtained from BRL
(Fullinsdorf, Switzerland) and kept under specific-pathogen-free conditions.
Animal experiments were performed according to the guidelines of the Veteri-
nary Office of Zurich, Switzerland. Tumor xenografts were raised by subcuta-
neous injection of 107 MDA-MB-231 or Colo-320 cells into the lateral flanks
of the mice under ether anesthesia. Growing tumors were measured with cali-
pers, and the approximate tumor volume was calculated by use of the following
formula: volume (mm3)  length × width2/2. Once tumors had reached an
average size of 75 mm3, mice were randomly assigned to treatment groups
matched for equal mean tumor volumes. Oligonucleotides were injected intra-
peritoneally at a dose of 20 mg/kg per day over a period of 3 weeks. MDA-
MB-231 tumors were measured after treatment for 0, 8, 13, 18, and 22 days,
while Colo-320 tumors were measured after 0, 6, 11, 15, and 21 days.
Detection of Bcl-2 and Bcl-xL Proteins in Tumor
Xenografts
After 2 weeks of treatment as described above, mice were killed by cervical
dislocation, and their tumors were removed, immersed in Hanks’ balanced salt
solution, and snap-frozen in liquid nitrogen. One half of each tumor was ana-
lyzed by immunohistochemical staining for Bcl-2 and Bcl-x; the other half was
lysed and used for western blotting of Bcl-2 and Bcl-xL.
For immunohistochemistry, 5-m tissue sections were cut in a cryostat, placed
on siliconized glass slides, air-dried, fixed with acetone for 10 minutes, and
stored at −70 °C. Bcl-2 was stained by incubating rehydrated sections with
primary fluoresceinated mouse monoclonal antibodies against human Bcl-2
(clone 124; Dako Diagnostics AG), followed sequentially by rabbit polyclonal
anti-fluorescein isothiocyanate antibodies (Dako Diagnostics AG) and alkaline
phosphatase-labeled donkey anti-rabbit Ig antibodies (Jackson Laboratories,
West Grove, CA). Bcl-x was stained with the use of polyclonal rabbit anti-Bcl-x
antibodies (Transduction Laboratories). Primary rabbit antibodies were revealed
by sequential incubation with alkaline phosphatase labeled goat anti-rabbit Ig
antibodies and donkey anti-goat Ig antibodies (Jackson Laboratories). Dilutions
of the affinity-purified secondary and tertiary antibodies were made in Tris-
buffered saline containing 5% normal mouse serum. Alkaline phosphatase was
visualized with the use of naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic
acid-2-methoxy anilide) phosphate and new fuchsin as substrate. Endogenous
alkaline phosphatase was blocked by levamisole. Color reactions were per-
formed at room temperature for 15 minutes with reagents (Sigma Chemical Co.).
Sections were counterstained with hemalum, and coverslips were mounted with
glycerol and gelatin.
For the determination of the levels of Bcl-2 and Bcl-xL proteins in tumor
lysates, tumors were homogenized with the use of a Polytron PT 3000 (Kine-
matica AG, Littau, Switzerland), and protein extraction and immunoblotting
were performed as described above under the heading entitled “Western Blot
Analysis.”
Detection of Apoptosis in Tumor Xenografts
For TUNEL (i.e., terminal deoxynucleotidyl transferase-mediated deoxyuri-
dine triphosphate-digoxigenin nick end labeling) staining, formalin-fixed and
paraffin-embedded tumor sections (4 m) were deparaffinized and rehydrated by
standard procedures. The tissues were rinsed briefly in Tris-buffered saline (i.e.,
0.15 M NaCl and 50 mM Tris–HCl [pH 7.4]) and digested with 30 g/mL
proteinase K (Boehringer Mannheim GmbH, Mannheim, Germany) in Tris-
buffered saline for 20 minutes at room temperature. After being washed in
distilled water for 10 minutes, the sections were equilibrated for 15 minutes in
TdT reaction buffer (i.e., 200 mM potassium cacodylate, 2.5 mM CoCl2, 0.25
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mg/mL BSA, and 25 mM Tris–HCl [pH 6.6]). The sections were then covered
with the TUNEL reagent mix (62.5 U/mL calf thymus TdT [Boehringer Mann-
heim GmbH] and 3.75 nmol/mL digoxigenin-11-deoxyuridine triphosphate in
TdT reaction buffer) and incubated for 1 hour at 37 °C in a water-saturated
atmosphere. The sections were washed for 10 minutes with 2× standard saline
citrate at 40 °C, rinsed with Tris-buffered saline, and preincubated with blocking
buffer (2% BSA and 0.3% Triton X-100 in Tris-buffered saline) for 30 minutes
at room temperature. For the detection of digoxigenin, sections were treated for
1 hour with alkaline phosphatase-labeled Fab fragments of affinity-purified
sheep anti-digoxigenin antibodies (1 U/mL blocking buffer at room tempera-
ture). After a further washing step with Tris-buffered saline, the red reaction
product was developed under visual control with the use of naphthol AS-BI
phosphate and new fuchsin as substrate. Endogenous alkaline phosphatase was
blocked by levamisole. After being counterstained with hemalum, coverslips
were mounted with glycerol–gelatin. Tissue sections from human tonsils, typi-
cally showing apoptotic cells, were used as positive controls.
Statistical Analysis
If not stated otherwise, data represent the mean and 95% confidence interval
(CI) of at least three independent determinations. In vitro growth assays were
analyzed with the use of analysis of variance (ANOVA) for repeated measure-
ments with the two within-factors concentration and treatment. Paired t tests
were used to determine the statistical significance of the antisense effect on cell
death compared with the control treatment, P values of less than .05 were
considered to be statistically significant, and all statistical tests were two-sided.
The effect of antisense oligonucleotide 4625 and control oligonucleotide 4626 on
tumor growth in mice was analyzed with the use of ANOVA for repeated
measurements. Within-factor time and between-factor treatment were compared
by use of Bonferroni–Dunn post-hoc tests.
RESULTS
Inhibition of bcl-2 and bcl-xL mRNA and Protein
Expression by Oligonucleotide 4625
Oligonucleotide 4625 is 100% complementary to the bcl-2
mRNA and has three base mismatches to the bcl-xL mRNA, two
of which were modified by 2-MOE residues. Based on this
design, it has the potential to hybridize to both mRNAs and to
inhibit the expression of both genes. To demonstrate this bispe-
cific activity, we treated MDA-MB-231 breast carcinoma cells
expressing high levels of Bcl-2 and Bcl-xL with oligonucleo-
tides, and we determined bcl-2 and bcl-xL mRNA by reverse
transcription–PCR. Samples treated with antisense oligonucleo-
tide 4625 showed markedly reduced levels of both bcl-2 and
bcl-xL mRNAs compared with untreated samples or samples
treated with control oligonucleotide (Fig. 1, A). For precise
quantification of sequence-specific inhibition of mRNA expres-
sion, real-time PCR was performed. Antisense oligonucleotide
4625 reduced bcl-2 and bcl-xL mRNA in a dose-dependent man-
ner, as determined 20 hours after the start of transfection (Fig. 1,
B). The maximal inhibition was achieved with 900 nM oligo-
nucleotide 4625 and was 86% (95% CI  79% to 93%) and
77% (95% CI  60% to 94%) for bcl-2 and bcl-xL, respec-
tively. The concentrations at which mRNA expression was in-
hibited by 50% (IC50 values) were 250 nM and 500 nM (data not
Fig. 1. Inhibition of bcl-2 and bcl-xL messenger RNA (mRNA) and protein
expression in MDA-MB-231 breast carcinoma cells. A) Cells were treated for 20
hours with antisense oligonucleotide 4625 or control oligonucleotides 4626 and
4258 at a concentration of 600 nM. Cells were harvested, and mRNA levels of
bcl-xL and bcl-2 were determined by reverse transcription–polymerase chain
reaction. 2-Microglobulin (2-MG) was used as a control for RNA quantity
and integrity. Bands are shown from one representative experiment of three
experiments. B) Cells were treated for 20 hours with antisense oligonucleotide
4625 or control oligonucleotides 4626 and 4258 at the concentrations indicated
(nM). Cells were harvested, and mRNA levels of bcl-xL (solid bars) and bcl-2
(open bars) were assessed by reverse transcription followed by real-time PCR
quantification. The levels in untreated cells measured under identical experi-
mental conditions were taken as 100%. Data represent the mean and 95% con-
fidence interval (n  3). C) Cells were treated for 40 hours with 600 nM
antisense oligonucleotide 4625 or control oligonucleotides 4626 or 4258. Cells
were harvested, and Bcl-2 and Bcl-xL protein levels were determined by western
blotting. Bands from one representative experiment are shown; numbers indi-
cate the mean and 95% confidence interval (n  3) given as percentage of the
Bcl-2 and Bcl-xL levels in untreated cells. -Actin was used as a loading control.
Bcl-xL migrated at 31 kilodaltons (kd), Bcl-2 at 28 kd, and -actin at 48 kd.
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shown). The control oligonucleotides 4626 and 4258 had only
marginal effects on bcl-2 and bcl-xL mRNA expression, indi-
cating that the bispecific activity of oligonucleotide 4625 was
sequence specific and was not related to unspecific gene-
regulatory events. On the protein level, 600 nM oligonucleotide
4625 reduced Bcl-2 and Bcl-xL expression to 25% (95% CI 
16% to 34%) and 20% (95% CI  14% to 26%), respectively,
when measured 40 hours after the start of transfection (Fig. 1,
C). Again, the control oligonucleotides 4626 and 4258 did not
substantially affect Bcl-2 and Bcl-xL protein levels and, in all
further experiments, only oligonucleotide 4626 was used as a
control. Bcl-xL migrated as a doublet, and both bands were
diminished by antisense treatment. Bcl-xS, a pro-apoptotic
splice variant of the bcl-x gene, was not detectable under these
conditions (data not shown).
Inhibition of Tumor Cell Growth by Oligonucleotide 4625
in Lung, Breast, Colorectal, and Prostate Carcinoma Cells
and in Malignant Melanoma Cells
Bcl-2 and Bcl-xL are survival factors protecting cells from
apoptosis induced by a variety of exogenous and endogenous
stimuli. Having demonstrated the bispecific activity of oligo-
nucleotide 4625 on the level of bcl-2 and bcl-xL mRNA and
protein, we further examined its ability to inhibit the in vitro
growth of a series of cell lines derived from lung, breast, colo-
rectal, and prostate carcinomas and from malignant melanoma.
As measured in MTT assays 72 hours after the start of transfec-
tion, oligonucleotide 4625 inhibited the growth of all cell lines in
a dose-dependent manner, with IC50 values ranging from 90 to
730 nM (Fig. 2). At a concentration of 800 nM, the levels of
inhibition ranged from 57% for LoVo cells to 93% for Colo-320
cells. With the exception of LoVo cells (P  .150), the inhibi-
tion of cell growth was statistically significant (P values ranging
from .024 to .004) as compared with control oligonucleotide
4626. The nonspecific cytostatic effect of oligonucleotide 4626
was comparatively low. The optimal antisense con-
centration, which is defined by a maximum differ-
ence in cell growth inhibition achieved with oligo-
nucleotides 4625 and 4626, ranged from 400 to
600 nM.
Induction of Tumor Cell Death and Apoptosis
by Oligonucleotide 4625 in Lung, Breast,
Colorectal, and Prostate Carcinoma Cells and
in Malignant Melanoma Cells
To investigate whether cell growth inhibition
was due to the induction of cell death and, more
specifically, to apoptosis, we analyzed propidium
iodide uptake in unfixed cells and DNA content in
permeabilized cells by flow cytometry 72 hours after the start of
transfection with 600 nM oligonucleotides. Antisense treatment
induced death in all nine cell lines, although at different rates
(Fig. 3, A). Uptake of propidium iodide was highest in A-375
cells (77%), LoVo cells (72%), and Colo-320 cells (65%) and
less pronounced in SW2 cells (36%) and PC-3 cells (32%). The
effect of oligonucleotide 4625 was statistically significantly
stronger when compared with that of the control oligonucleotide
4626 (P values between .010 and .001). Cell death was mainly
due to the induction of apoptosis (Fig. 3, B and C). After anti-
sense treatment, a large fraction of cells with typical sub-Go/G1
DNA content indicative of apoptosis was observed in Colo-320
cells (64%), A-375 cells (61%), and LoVo cells (51%). Cells
with fragmented DNA were less frequent in the SW2 (20%) and
PC-3 (8%) cell lines. Differences between antisense and control
treatment were statistically significant (P values between .001
and .009) except for PC-3 cells (P  .053). Further proof that
cell death induced by oligonucleotide 4625 treatment mainly
occurred by apoptosis was provided by Hoechst staining of nu-
clei, which revealed intense nuclear fragmentation and conden-
sation (left inset in Fig. 3, C). With the exception of LoVo cells,
which showed a strong response to antisense treatment in the cell
death assays but were less responsive when examined in MTT
assays, these data reflected the results from the growth-
inhibition assays mentioned above. Treatment with the control
oligonucleotide 4626 decreased the number of viable cells to a
much lesser extent.
In Vivo Antitumor Activity of Oligonucleotide 4625
Against Breast and Colorectal Carcinoma Xenografts
To determine whether the potent cell death-inducing effect of
antisense oligonucleotide 4625 observed in vitro translated into
therapeutic efficacy in vivo, we investigated its activity in nude
mice bearing established subcutaneous MDA-MB-231 breast
carcinoma or Colo-320 colorectal carcinoma xenografts. Oligo-
Fig. 2. Inhibition of tumor cell growth in lung carcinoma (SW2
and NCI-H125), breast carcinoma (MDA-MB-231 and MCF-
7), colorectal carcinoma (Colo-320 and LoVo), prostate carci-
noma (PC-3 and C4–2), and malignant melanoma (A-375) cell
lines. Cells were treated for 72 hours with increasing concen-
trations of antisense oligonucleotide 4625 (solid symbols) or
control oligonucleotide 4626 (open symbols), and cell growth
was measured in quadruplicate by use of the MTT [i.e., 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] re-
agent. Data represent the mean and 95% confidence interval (n
 3). P values were determined with the use of analysis of
variance for repeated measurements.
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nucleotides were injected intraperitoneally at a dose of 20 mg/kg
per day over a period of 3 weeks. Antisense treatment statisti-
cally significantly inhibited the growth of both breast carcinoma
and colorectal carcinoma xenografts. At the end of the 3-week
treatment period, oligonucleotide 4625 had diminished the
growth of MDA-MB-231 xenografts (Fig. 4, A) by 51% (95%
CI  28% to 74% ) (P  .016) and of Colo-320 xenografts
(Fig. 4, B) by 59% (95% CI  44% to 74%) (P<.001) as
compared with control oligonucleotide 4626. There was no sta-
tistically significant difference in the growth of untreated and
control oligonucleotide 4626-treated tumors (P  .65 and P 
.78, respectively). No signs of treatment-related toxicity to the
animals, such as inflammation, bleeding, hepatomegaly and
splenomegaly, or weight loss, were observed over the course of
the study.
Inhibition of Bcl-2 and Bcl-xL Protein Expression and
Induction of Apoptosis by Oligonucleotide 4625 in Tumor
Xenografts
To provide evidence that the antitumor activity of oligo-
nucleotide 4625 was due to its ability to downregulate Bcl-2 and
Bcl-xL in vivo, we analyzed tumor xenografts treated for 2
weeks as described above by immunohistochemistry. For this
purpose, MDA-MB-231 breast carcinoma xenografts were cho-
sen because they express Bcl-2 and Bcl-xL at readily detectable
levels but no splice variant Bcl-xS (data not shown). Fig. 5,
A–D, shows a representative tumor xenograft in which Bcl-2-
and Bcl-x-positive cells were heterogeneously distributed across
the tumor sections. Whereas large areas with intense staining for
Bcl-2 and Bcl-x were present in control treated tumors, anti-
sense-treated tumors showed markedly less intense staining for
both proteins in the majority of the cells, and this finding did not
depend on the cell density (Fig. 5, A–D). Tumor sections pro-
cessed with secondary and tertiary antibodies alone were used as
negative controls (Fig. 5, E and F). Fig. 5, G, shows an immu-
noblot of whole-tumor lysates from representative tumor xeno-
grafts confirming the inhibition of target protein expression
shown by immunostaining. The lower inhibitory effect on Bcl-xL
expression might be due to the presence of mouse stromal and
endothelial cells in the tumor lysate and the fact that, in contrast
to Bcl-2, available antibodies do not discriminate between hu-
man and mouse Bcl-xL.
To determine whether oligonucleotide 4625 induced apopto-
sis in the tumors, we performed TUNEL staining 1 week after
the start of treatment to detect the presence of apoptotic nuclei in
situ. Although in all tumors few isolated TUNEL-positive nuclei
were visible, oligonucleotide 4625 antisense-treated tumors
clearly showed more such apoptotic nuclei (Fig. 5, H) than did
control oligonucleotide 4626-treated tumors (Fig. 5, I). Thus, as
expected from its proposed mechanism of action, antisense oli-
gonucleotide 4625 reduced Bcl-2 and Bcl-xL protein levels and
induced apoptosis in the tumor xenografts.
DISCUSSION
The bcl-2 or bcl-xL antisense compounds currently under
clinical investigation are specific for either bcl-2 or bcl-xL, a
property limiting their therapeutic efficacy in the frequent cases
of advanced tumors where both cell death antagonists are ex-
pressed. The rationale behind the antisense approach described
in our study was the use of an antisense oligonucleotide with the
ability to simultaneously downregulate bcl-2 and bcl-xL expres-
sion. This property is likely to be of therapeutic benefit and may
have a broader applicability in cancer therapy compared with the
bcl-2- and bcl-xL-monospecific oligonucleotides described so
far. We have recently designed the bcl-2/bcl-xL-bispecific anti-
sense oligonucleotide 4625 and reported its ability to simulta-
neously inhibit the expression of bcl-2 and bcl-xL and induce
apoptosis in small-cell lung carcinoma and lung adenocarcinoma
cells (25). Here, we describe the use of this bispecific antisense
compound to inhibit the growth and induce apoptosis in tumor
cells of diverse histologic origins in vitro and in vivo. We have
Fig. 3. Induction of tumor cell death and apoptosis in lung carcinoma (SW2 and
NCI-H125), breast carcinoma (MDA-MB-231 and MCF-7), colorectal carci-
noma (Colo-320 and LoVo), prostate carcinoma (PC-3 and C4–2), and malignant
melanoma (A-375) cell lines. Cells were treated for 72 hours with 600 nM
antisense oligonucleotide 4625 (solid symbols) or control oligonucleotide 4626
(open symbols). Cell death (A) and apoptosis (B) were assessed on the basis of
propidium iodide uptake into unfixed or ethanol-fixed cells, respectively, by use
of a flow cytometer. Data represent the mean and 95% confidence interval of
three determinations. Paired t tests were performed to determine statistical sig-
nificance. C) Histograms illustrating the appearance of an apoptotic sub-G0/G1
cell population upon treatment with antisense oligonucleotide 4625; insets:
Hoechst stainings of nuclei confirming the apoptotic morphology of antisense-
treated cells. Representative examples of MDA-MB-231 cells from the experi-
ment described in this legend are shown.
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tested nine cell lines derived from lung, breast,
colorectal, and prostate carcinomas, representing
the four most prevalent and malignant tumors, as
well as cells from malignant melanoma. These cell
lines express distinct levels of Bcl-2 and Bcl-xL
that were representative of the respective tumor
types (28–32).
As shown by conventional reverse transcrip-
tion–PCR and real-time PCR, oligonucleotide
4625 efficiently inhibited bcl-2 and bcl-xL mRNA expression in
MDA-MB-231 breast adenocarcinoma cells in a dose-dependent
manner. Northern blot analysis yielded identical results for the
bcl-xL mRNA, whereas the inhibitory effect of oligonucleotide
4625 on bcl-2 mRNA expression could not be evaluated, since
the signal was masked by strong background corresponding to
the 28S rRNA (data not shown). As expected from its comple-
mentarity to the target sequences (no mismatch to bcl-2 and
three mismatches to bcl-xL), the IC50 value for inhibiting
mRNA expression was higher for bcl-xL than for bcl-2 (500 nM
versus 250 nM). However, 900 nM oligonucleotide 4625 re-
duced both bcl-2 and bcl-xL mRNA levels to a similar extent,
suggesting that the 2-MOE-modified nucleotide building block
could indeed largely overcome the three mismatches to bcl-xL to
yield a truly bcl-2/bcl-xL-bispecific antisense compound. On the
protein level, oligonucleotide 4625 was effective equally on
Bcl-2 and Bcl-xL already at a concentration of 600 nM, a finding
possibly reflecting differences in the half-lives of these proteins.
In all tumor cell lines tested, treatment with 600 nM antisense
oligonucleotide 4625 resulted in cell death, which was mainly
due to the induction of apoptosis. The quantitative differences in
the overall rate of cell death and apoptosis observed in some cell
types suggest that cell death did not always occur by classic
apoptosis. These differences may also have been due to the fact
that, at more advanced stages, the apoptosis process cannot be
distinguished from other forms of cell death (27). The colorectal
carcinoma cell line Colo-320 and the malignant melanoma cell
line A-375 were the most susceptible to antisense treatment,
while the SW2 small-cell lung carcinoma cell line and the PC-3
prostate carcinoma cell line were the least susceptible. At pres-
ent, we cannot exclude cell type-specific differences in oligo-
nucleotide uptake and intracellular distribution (33), but the dif-
ferential responsiveness of the cell lines to the inhibition of
Bcl-2 and Bcl-xL expression suggests differences in the way in
which they respond to changes in the life–death rheostat main-
tained by pro- and anti-apoptotic Bcl-2 family members. We
further measured Bcl-2, Bcl-xL, and Bax levels by western blot-
ting in all the cell lines used in this study (data not shown), but
we could not establish a positive or negative association between
the basal levels of these proteins and the results obtained in the
cell viability and apoptosis assays. In view of the complexity of
the apoptosis machinery and the fact that a great number of pro-
and anti-apoptotic proteins are engaged in apoptosis regulation,
this finding is not surprising. Intraperitoneal injection of oligo-
nucleotide 4625 statistically significantly inhibited the growth of
established subcutaneously growing MDA-MB-231 breast and
Colo-320 colorectal carcinoma xenografts in nude mice. The
injected dose of 20 mg/kg per day of oligonucleotide 4625 was
chosen because it proved to be both effective and well tolerated
in a study with a similar type of antisense oligonucleotide tar-
geting the C-raf kinase (34). The antitumor effect of oligo-
nucleotide 4625 was associated with a reduction in Bcl-2 and
Bcl-xL proteins in the carcinoma xenografts, as demonstrated by
immunostaining in situ and western blot analysis of whole-
tumor lysates. The observation that the overall cell density on
the tumor sections was somewhat lower in the antisense-treated
than in the control-treated xenografts may be the result of in-
creased apoptotic cell loss and the subsequent replacement of
tumor tissue by connective tissue in the antisense-treated tumors.
In situ TUNEL staining indeed revealed that tumors from mice
treated with oligonucleotide 4625 showed clearly more apop-
totic cells than control tumors from mice treated with oligo-
nucleotide 4626. GenBank analysis revealed that oligonucleo-
tide 4625 has more than six mismatches to the murine bcl-2 and
bcl-xL mRNAs. Thus, despite the promising antitumor effect
achieved with our antisense compound, we cannot draw conclu-
sions regarding toxicity related to the reduction in Bcl-2 and
Bcl-xL in normal tissues. In recent clinical studies (35,36), how-
ever, a bcl-2-monospecific antisense oligonucleotide revealed
only minimal side effects, which were attributed mainly to the
biochemical properties of the oligonucleotide’s phosphorothio-
ate backbone.
In a recent study (37), support was provided for the hypoth-
esis that high-level expression of Bcl-2 and Bcl-xL confers a
chemoresistant phenotype on tumor cells. Attempts to compare
the expression of Bcl-2 or other anti-apoptotic Bcl-2 family
members in tumor cells before treatment and at the time of
relapse have demonstrated an apparent increase in Bcl-2 and a
survival advantage for cells containing higher Bcl-2 levels (38).
The complexity of dealing with a great number of proteins in-
Fig. 4. Growth inhibition of tumor xenografts. Nude mice bear-
ing established, subcutaneously growing MDA-MB-231 breast
(A) or Colo-320 colorectal (B) carcinoma xenografts either re-
mained untreated (open circles) or were treated with 20 mg/kg
per day of antisense oligonucleotide 4625 (solid squares) or
control oligonucleotide 4626 (open squares) administered in-
traperitoneally over a period of 3 weeks. Tumor size was mea-
sured, and the relative increase in tumor volume was calculated
at the time points indicated. Data represent the mean and 95%
confidence interval (n  number of animals per group). P
values were determined with the use of analysis of variance for
repeated measurements.
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volved in the apoptosis machinery that serve opposing functions
limits the use of Bcl-2 and Bcl-xL as independent prognostic
factors and suggests the examination of other proteins, such as
the pro-apoptotic Bcl-2 family members. This issue, however,
has not always been addressed consistently; probably, for this
reason, clinical correlative studies have not uniformly demon-
strated an adverse prognostic role for Bcl-2, and some have even
shown that overexpression of Bcl-2 in tumors was associated
with a favorable prognosis (39–41). Another important issue
arises from the fact that, apart from the anti-apoptotic protein
Bcl-xL, the bcl-x gene also encodes for pro-apoptotic Bcl-xS by
alternative splicing of the bcl-x pre-mRNA (42). Although Bcl-xL
seems to be the prevalent form in tumor cells and the relevance
of Bcl-xS as a tumor suppressor is rather unclear (43), the po-
tential to target the bcl-xS mRNA in tumor cells could be a
fundamental drawback of the bcl-x antisense oligonucleotides
described so far. This drawback may not apply to oligonucleo-
tide 4625 for the following reasons: 1) The identified high ho-
mology region on the bcl-xL mRNA is localized at a splice
junction site of bcl-x, and this sequence occurs neither in the
mRNA of Bcl-xS nor in the mRNAs of other pro-apoptotic
Bcl-2 family members; and 2) in the bcl-x pre-mRNA, the se-
quence targeted by oligonucleotide 4625 is interrupted by an
intron, excluding the possibility that this oligonucleotide hybrid-
izes to the bcl-x pre-mRNA.
In summary, our results demonstrate that state-of-the-art an-
tisense technology offers a powerful approach to simultaneously
target the expression of the two major anti-apoptotic proteins
Bcl-2 and Bcl-xL with a single, rationally designed oligonucleo-
tide. The functional advantage of oligonucleotide 4625’s
bispecificity and its broad activity against tumor cells of diverse
histologic origins suggest the use of this antisense compound in
cancer therapy.
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